Paula K. Cobb is the Chief Business Officer at Affinia Therapeutics. Between 2016 and 2019, Ms. Cobb held positions as Executive Vice President, Corporate Development and Chief Operating Officer at Decibel Therapeutics. Before Decibel, between 2003 and 2016, she held numerous positions with Biogen, including Senior Vice President, Rare Disease Group, Senior Vice President, MS Franchise Strategy and Vice President, Program Leadership & Management. She also served on the Board of Directors of Nightstar Therapeutics plc from 2018 until it was acquired by Biogen in 2019. Ms. Cobb earned her B.A. from Amherst College and her M.B.A. from Harvard University’s Graduate School of Business Administration.